Cell Line Development Market is forecast to reach a valuation of US$ 4.7 Billion in 2022 | FMI

[329 Pages Report] According to a latest research by Future Market Insights (FMI), the global cell line development market size is anticipated to account for over US$ 7,200 Mn, in terms of value, by 2028 end. The report on cell line development market further projects significant growth potential with CAGR at 7.2% through 2028.

According to International Agency for Research on Cancer, the number of new cancer cases per year is expected to rise to 23.6 million by 2030 globally. In recent times, cell line development and its applications are considered as potential tools in oncology research. Cell lines are projected to be used for development of new treatment pathway for various disease including cancer and neurological diseases.

Rapid increase in prevalence of cancer and neurology disorders and lack of efficient treatment solution for these diseases has created the need of more advanced and efficient treatment pathway. Companies and government organizations are investing on research and development activities and are also focusing more on cell line development in search of new cellular pathway to develop novel drugs. The increased spending on biosimilar R&D from exiting biopharmaceutical companies would provide boost to cell line development market.

In recent time the contract research organizations are focusing on cell line development and cell line research activities. According to National Institutes of Health (NIH) the estimated total federal spending on all type of stem cell line research for 2017 is US$ 1.58 Bn. In developing countries like India, government is supporting cell line development through national funding agencies like Department of Biotechnology (DBT), Indian Council of Medical Research (ICMR), and Department of Science and Technology (DST).

To remain ahead of your competitors, request for a sample – https://www.futuremarketinsights.com/reports/sample/rep-gb-7566

Regenerative medicines are the next generation treatment solution and Cell Line Development or Cell Culture is a vital part for regenerative medicine. Increasing demand of regenerative medicines in cancer treatment would positively impacting the growth of Cell Line Development market over the forecast period.

The biopharmaceutical companies operating in development of novel drug line are expected to hold promising revenue opportunity in cell line development market.

Future Market Insights (FMI) has segmented the cell line development market based on product type, cell line source type, end user, type of cell line and region.

Product type segment in cell line development market is segmented into media and reagents, equipment and accessories. Reagents and Media are required from incubation to preservation of cell lines. These products are expensive and have repetitive use in cell culture or bio-production. Reagent and media segment in cell line development market is expected witness noteworthy growth in terms of revenue owing to rapid increase in demand in cell culture and cell based assays.

Cell line development market by cell line source is categorized into mammalian cells and non-mammalian cells. Mammalian cell line development is anticipate to witness significant growth in overall cell line development market. This growth of mammalian cells segment in cell line development market is driven by increased production of biologics drugs which require mammalian cells. Increasing antibody production is the major driving factor behind the growth of mammalian cell lines segment in cell line development market.

Mammalian cell lines are used to create therapeutic proteins through genetic building and antibodies through viral infection. For example, Gaucher’s disease, which is a genetic disorder characterized by lack of β-glucocerebrosidase enzyme and can be treated by Cerezyme which is a recombinant enzyme produces in mammalian cell lines. Mammalian cell lines are also useful in production of antibodies and other therapeutic agents such as specific binding proteins that can neutralize disease causing agents in the body. For example Under cell line type segment in cell line development market, recombinant cell line development are the most demanding type of cell line due to large application in biologics production, protein interaction, gene activation, toxicity testing and drug screening.

Ask from Market Research Expert – https://www.futuremarketinsights.com/ask-question/rep-gb-7566

Growing application recombinant cell line development in drug toxicity testing is expected to boost the growth of overall cell line development during the forecast period

North America and Europe cell line development market will dominate in owing to increasing government funding in cell line development research and rising spending on biosimilar developments. Asia Pacific cell line development market is expected to grow at a high growth rate due to increased number of research organization engaged in novel biologics and biosimilar fastest revenue growth in overall cell line development market.

The Asia Pacific region in Cell line development market is anticipate to witness increasing demand of biopharmaceuticals and regenerative medicines are expected to boost the growth of the cell line development market.

FMI’s report tracks some of the key companies operating in the cell line development market, such as Selexis SA, GE Healthcare, Corning Incorporated, Thermo Fischer Scientific, Inc., American Type Culture Collection (ATCC), Lonza (Sartorius Stedim Biotech S.A.), Danaher Corporation, Merck KGaA, WuXi Biologics.

Key Market Segments Covered in Cell line development Market Research By Product Type:

  • Reagent and Media
  • Equipment
  • Accessories and consumables

By Source Type:

  • Mammalian cell line
  • Non-mammalian cell line

By End User:

  • Biopharmaceutical Companies
  • Contract Research Organizations
  • Academics and Research Institutes
  • Biotechnology Companies

For in-depth insights, Download a PDF Brochure – https://www.futuremarketinsights.com/reports/brochure/rep-gb-7566

By Cell Lines:

  • Recombinant cell lines
  • Hybridomas
  • Continuous cell lines
  • Primary cell lines

About FMI:

Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.

Contact Us:
Future Market Insights,
Unit No: 1602-006,
Jumeirah Bay 2,
Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers,
Dubai,
United Arab Emirates
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs

Pharma Grade Synthetic Camphor Market is projected to register the growth of 4.2% CAGR from 2022 to 2028

[253 Pages Report] According to the latest research by the company, the global pharma-grade synthetic camphor market size is anticipated to be valued at US$ 532.0 Mn, by 2028 end.

The report on pharma-grade synthetic camphor market further projects significant growth potential with average year-on-year growth rate pegged at 4.1% through 2028.

Growing demand for topical pain management products is expected to propel the growth of pharma-grade synthetic camphor market. Pharma-grade synthetic camphor is used in many topical analgesic products such as oils, ointments, chest rubs, and gel.

To remain ‘ahead’ of your competitors, request for a sample @ https://www.futuremarketinsights.com/reports/sample/REP-GB-7564

These pharma-grade synthetic camphor pain management products are experiencing significant growth due to lesser side effect compare to oral analgesic and expanded retail channel access. Increasing self-medication rate and availability of cost-effective camphor contained OTC analgesic favors the growth of pharma-grade synthetic camphor market growth.

pharma grade synthetic camphor market

Growing incidence of infectious diseases such as cold, flu augmented the use of cold sore remedies, nasal decongestants, topical expectorants etc. which in turn would drive the growth of pharma-grade synthetic camphor market. Increasing use of private labeled topical products containing camphor push the demand for pharma-grade synthetic camphor.

For critical insights, request for PDF Brochure – https://www.futuremarketinsights.com/reports/brochure/rep-gb-7564

Private label analgesic is gaining popularity in the U.S. market as they do not require FDA approval and strong promotion activities by retailers. Walgreens Ultra Strength Muscle Rub (4% camphor), Salonpas pain relieving patch (1.2% camphor) are the examples of private label analgesic which contain camphor. Surge in commodity export, economic growth and production capacity are expected to boost the growth of pharma-grade synthetic camphor market.

However, regulatory restrictions on the use of camphor in the medicine of pharmaceutical products would considerably impact the growth of pharma-grade synthetic camphor market. Moreover, increasing raw material prices are expected to hamper the growth of pharma-grade synthetic camphor market. Thus, growing prices of raw materials i.e. alpha pinene or turpentine oil is a major challenge for the manufacturers of pharma-grade synthetic camphor.

Company has segmented the global pharma-grade synthetic camphor market into formulation, application, distribution, and regions. Based on the formulation, pharma-grade synthetic camphor market is segmented into topical and inhalation. The topical segment is expected to represent a highest revenue share in pharma-grade synthetic camphor market as high number of marketed products and vast applications.

Applications of pharma-grade synthetic camphor included in the report are respiratory disorders applications, muscular rheumatism, counterirritant & antipruritic and others (topical analgesic, cold sores, minor burns, antifungal, hemorrhoids, topical antitussive & expectorant, astringent, rubefacient, etc.). Others segment expected to contributes highest market value in global pharma-grade synthetic camphor market. Based on the distribution channel, pharma-grade synthetic camphor market is segmented into conventional B2B and online B2B channel.  In terms of revenue, conventional B2B segment would hold significant revenue share in pharma-grade synthetic camphor market over the forecast period.

On the basis of region, the global pharma-grade synthetic camphor market has been segmented into North America, Latin America, Western Europe, Eastern Europe, the Asia Pacific excluding China & Japan, China, Japan, and the Middle East & Africa. North America is expected to contribute highest revenue share in global pharma-grade synthetic camphor market.

The demand of pharma-grade synthetic camphor has increased in North America, as increasing production of camphor contained private label and OTC products. China is expected to witness the highest growth rate in pharma-grade synthetic camphor market due to presence of the larger number of pharma-grade synthetic camphor manufactures. Pharma-grade synthetic camphor manufactures are mainly concentrated in China and India and they export their chemicals to the U.S. and Europe. Moreover, due to its growing contribution to the global industry, Asia Pacific is emerging as a focused destination for global manufacturers of camphor and related chemicals.

Buy Now/Purchase @ https://www.futuremarketinsights.com/checkout/7564

Report tracks some of the key companies operating in the global pharma-grade synthetic camphor market. Representative players included in the global pharma-grade synthetic camphor market report are Merck KGaA, Oriental Aromatics Limited, Saptagir Camphor Limited, Mangalam Organics Limited, Nippon Fine Chemical Co., Ltd., Rochem International, Inc., Spectrum Chemical Mfg. Corp., Aldon Corporation, Prinova Group LLC. and Fengchen Group Co., Ltd. Manufactures are focusing on improvement of the supply chain which expected to provide huge opportunities to them over the forecast period.

Why Future Market Insights?

• Comprehensive analysis on evolving purchase pattern across different geographies
• Detailed insights of market segments and sub-segments for historical as well as forecast period
• A competitive analysis of prominent players and emerging players in the keyword market
• Detailed information about the product innovation, mergers and acquisitions lined up in upcoming years

Ground breaking research and market player-centric solutions for the upcoming decade according to the present market scenario

About FMI:

Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.

Contact Us:
Future Market Insights,
Unit No: 1602-006,
Jumeirah Bay 2,
Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers,
Dubai,
United Arab Emirates
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs

Next Generation Optical Biometry Devices Market is projected to rise at a CAGR of around 5.4% through 2028 | FMI

[248 Pages Report] Increasing incidence of eye diseases such as cataract and refractive errors coupled with rising number of eye care clinics and hospitals globally are factors increasing the adoption of next generation optical biometry devices.

With the advancement in the technology, next generation optical biometry devices have been developed aiding measurement of eyes before cataract and refractive surgeries. Earlier measurement by ultrasound technique was gold standard. However, unlike next generation optical biometry devices, ultrasound devices require direct contact of the probe, which lead to many eye infections.

The next generation optical biometry devices are automated and measure many parameters such as the axial length, anterior chamber depth, thickness of the lens, retinal thickness, pupil size and many more.

Request Sample@ https://www.futuremarketinsights.com/reports/sample/rep-gb-7556

The next generation optical biometry devices are an accurate alternative for the precise measurements and provide efficient results. Also the next generation optical biometry devices avoid the operator variations measurements.

Research indicates next generation optical biometry devices market is anticipated to account for revenues over US$ 450 Mn, by 2028 end. The report on next generation optical biometry devices projects market revenues to expand at a CAGR of 5.1% through 2028.

According to Prevent Blindness organization, ~25 Mn Americans having cataract require medical care every year in the U.S., hence boosting demand for next generation optical biometry devices.

Similar rising demand for next generation optical biometry devices is noted in UK with rising number of cataract surgeries. Increased demand for next generation optical biometry devices is noted in developing markets concurrent with access to eye care facilities.

Next generation optical biometry devices are all-in one devices used for evaluation of lens and refraction, of retina.

Ask from Market Research Expert – https://www.futuremarketinsights.com/ask-question/rep-gb-7556

Next Generation Optical Biometry Devices Market: Overview & Analysis

Rapid increase in number of probe infections due to usage of ultrasound devices, lead to post-operative errors fuelling demand for next generation optical biometry devices instead of ultrasound biometry devices.

Manufacturers of next generation optical biometry devices are introducing automated devices which are more efficient in measuring segments of eyes. Players in next generation optical biometry devices market are working on strengthening the software, which could provide detailed information about eye segments.

New next generation optical biometry devices introduced are taking into account irregularities and astigmatisms of the anterior and the posterior surfaces of the eye.

The next generation optical biometry devices uses a partially coherent wave that has approximately 9x the resolution of a 10 MHz sound wave, for precise measurement of axial length.

Hospitals end users segment account for 41.8% revenue share in the global Next Generation Optical biometry Devices market. Medical services and vision benefits offered under Medicare includes cataract surgeries; which will increase the demand of next generation optical biometry devices.

Increasing geriatric population and rising income in Japan is expected to surge the demand for more advanced Next Generation Optical biometry Devices. Japan Next Generation Optical biometry Devices market is estimated to create absolute $ opportunity worth approximately US$ 1.21 Mn between 2017 and 2028.

The company has segmented the global Next Generation Optical Biometry Devices Market into product type and end users. In terms of revenue, the swept source segment in product type in next generation optical biometry devices market report will account for significant revenue share over the forecast period.

In contrary, the Partial coherence interferometry (PCI) based next generation optical biometry devices segment in all the markets will exhibit limited investment opportunities through 2028 in next generation optical biometry devices market.

Next Generation Optical Biometry Devices Market: Key Players

The next generation optical biometry devices market report tracks some of the key companies, such as Carl Zeiss AG, Nidek Co Ltd, Haag-Streit AG(Metall Zug AG), Ziemer Ophthalmic Systems, Optovue, Incorporated, Topcon Corporation, TOMEY GmbH,  Movu Inc. (unit of Santec Corporation) , Newway Technology and  OCULUS Optikgeräte GmbH. The largest player in the next generation optical biometry devices market is Carl Zeiss AG with its IOL masters and Haag-Streit AG’s Lenstar.

Buy Now/Purchase @ https://www.futuremarketinsights.com/checkout/7556

Key Segments of Next Generation Optical Biometry Devices Industry SurveyNext Generation Optical Biometry Devices Market by Product Type

  • Swept-Source Optical Coherence Tomography (OCT) Based Biometers
  • Partial Coherence Interferometry (PCI) Based Biometers
  • Optical Low Coherence Reflectometry (OLCR) Based Biometers

Next Generation Optical Biometry Devices Market by End User

  • Hospitals
  • Ophthalmology Clinics and Specialized Eye Care Centers
  • Ambulatory Surgical Centers

About FMI:

Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.

Contact Us:
Future Market Insights,
Unit No: 1602-006,
Jumeirah Bay 2,
Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers,
Dubai,
United Arab Emirates
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs

Preterm Birth Diagnostic Test Kits Market is projected to reach U.S. $ 203.2 Mn by the end of 2028 with a cumulative CAGR of 7.6% from 2022-2028

[257 Pages Report] According to Future Market Insights (FMI), the global Preterm Birth Diagnostic Test Kits Market was worth US$ 121.3 Mn in 2021 and is expected to grow 1.6X during the forecast period. During the forecast period of 2022-2028, the market is expected to grow at a CAGR of 7.6%, with sales of US $ 203.2 Mn in 2028.

A new study by the company titled ‘Preterm Birth Diagnostic Test Kits Market: Global Industry Analysis 2013-2017 and Opportunity Assessment 2018-2028’, has listed out the key points being considered by preterm birth diagnostic test kits companies to emerge and stay sustainably profitable in the long run in the preterm birth diagnostic test kits market.

The global preterm birth diagnostic test kits market is expected to expand at a CAGR of 7.4% over the forecast period to reach a value of over US$ 200 Mn by 2028, and the North America preterm birth diagnostic test kits market is expected to remain as a main sink market for revenues. Europe is expected to remain as the main source market for preterm birth diagnostic test kits, as most of the preterm birth diagnostic test kits facilities are located in this region. However, with the increasing demand and cost-effective diagnostic options in countries such as China and India, and various countries of Asia Pacific and Middle-East, is fueling the growth of preterm birth diagnostic test kits market.

A sample of this report is available upon request @ https://www.futuremarketinsights.com/reports/sample/rep-gb-7551

Key Findings Presented in the Report on the Preterm Birth Diagnostic Test Kits Market

The report finds that approximately 115.4 million births occurred in 2017, out of which 11.1% births were preterm, which is approximately 12.8 million births. As per WHO, preterm birth complications are the leading cause of deaths amongst children under the age of 5, directly responsible for approximately 1 million death in 2015. Out of these, 3/4th of these deaths can be prevented with cost-effective interventions. The adoption rates for preterm birth diagnostic tests kits ranged from 2% to 15% distributed over various geographies. Majority of the existent patient pool are unaware about the cost-saving benefits of preterm birth diagnostic test kits, thus, a major portion on the preterm birth test kits market has remained untapped which remains open for manufactures of preterm diagnostic test kits to exploit the preterm birth diagnostic test kits market over the forecast period.

Analysis of the Preterm Birth Diagnostic Test Kits Market

For preterm birth diagnostic test kits, blood sample is the most common sample take for diagnosing preterm labor and premature rupture of membrane. Blood sample-based preterm birth diagnostic tests in preterm cases are the most common and widely accepted in the preterm birth diagnostic test kits end users. However, vaginal discharge sample type preterm birth diagnostic tests are gaining popularity for preterm birth diagnostic test kits.

Hospitals, outpatient clinics & diagnostic laboratories using preterm birth diagnostic tests are the primary point of contact for patients experiencing preterm birth symptoms. Hospitals are estimated to account for majority of the revenue share under the end users segment for preterm birth diagnostic test kits market in 2017, owing to being the primary healthcare facility for preterm cases. The prevalent cases of preterm birth, growing demand for cost-effective diagnostic options and preterm birth test kits, and success in clinical studies for developing a rapid preterm birth diagnostic test kits is expected to fuel the growth of the global preterm birth diagnostic test kits market over the forecast period.

Ask An Analyst @ https://www.futuremarketinsights.com/ask-the-analyst/rep-gb-7551

Activities across the preterm birth diagnostic test kits manufacturers are restricted to efficiency and specificity testing. The top activity associated with preterm birth diagnostic test kits manufacturers is joint collaboration with various organizations in order to spread awareness, further development, and test the sensitivity, specificity and efficiency of preterm birth diagnostic test kits.

Factors Impacting Growth of the Preterm Birth Diagnostic Test Kits Market

Rising focus on cost-effective diagnosis using preterm birth diagnostic test kits is expected to boost the growth of the preterm birth diagnostic test kits market. Preterm birth diagnostic test kits manufacturing companies focusing on spreading awareness about preterm birth diagnostic test kits and marketing preterm birth diagnostic test kits through campaigns and joint research studies is expected fuel the growth of the preterm birth diagnostic test kits market during the forecast period. However, Preterm birth diagnostic kits experience stiff competition from alternative product lines. Trans-vaginal scans, advanced ultrasound are some of the examinations adopted by healthcare providers over preterm birth diagnostic kits and would pose challenges to the growth of the preterm birth diagnostic test kits market.

Preterm Birth Diagnostic Test Kits Market: Companies

Some of the key preterm birth diagnostic test kits companies analyzed in this report titled Preterm birth diagnostic test kits market include Creative Diagnostics, Qiagen, Medixbiochemcia, Hologic Inc, Sera Prognostics, IQ Products, Biosynex, Nanjing Liming Biological Preparations Co Ltd, Clinical Innovations LLC, BIOSERV Diagnostics GmbH, Wuxi BioHermes Biomedical Technology Co. Ltd, and Anhui Deep Blue Medical Technology.

For in-depth competitive analysis, Buy Now – https://www.futuremarketinsights.com/checkout/7551

Preterm Birth Diagnostic Test Kits Market, By Category

Product:

  • ffN Test
  • PAMG-1 Test
  • IGFBP-1 Test

Sample:

  • Blood
  • Urine
  • Vaginal Discharge

End User:

  • Hospitals
  • Diagnostic Laboratories
  • Outpatient Clinics
  • Research Centers

More Trending Reports by Future Market Research :

HDL Cholesterol Kits Market : Sales in the global HDL Cholesterol Kits Market are slated to top US$ 568.1 Mn in 2022. Expanding at a healthy 4.8%CAGR, the market size is projected to total US$ 786.2 Mn by 2029.

Cryptococcal Antigen Lateral Flow Assay Test Market : The cryptococcal antigen lateral flow assay is a type of an immunochromotography test system, used to identify the capsular polysaccharide antigens of cryptococcus species present in serum and Cerebrospinal Fluid (CSF).

Dental Diagnostic and Surgical Equipment Market : Expanding at a CAGR of 7.3%, the global dental diagnostic and surgical equipment market is projected to increase from a valuation of US$ 11.2 Bn in 2021 to US$ 20.6 Bn by 2032.

About FMI:

Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 9-years.

Contact Us:
Future Market Insights,
Unit No: 1602-006,
Jumeirah Bay 2,
Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers,
Dubai,
United Arab Emirates
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs

Actinic Keratosis Treatment Market is expected to reach US$ 8.0 Bn by 2028, at a 7.0% CAGR through 2028

[275 Pages Report] The global Actinic Keratosis Treatment Market was valued at US$ 5.0 Bn in 2021 and is expected to reach US$ 8.0 Bn by 2028, finds Future Market Insights (FMI) in a recent market survey.

Global demand for actinic keratosis treatment, majorly driven by that in the U.S. and European countries, continues to grow at a strong rate. Poised for revenues of over US$ 4 Bn by the end of 2019, the global actinic keratosis treatment market will exhibit an impressive CAGR of 7% during the forecast period (2019 – 2029).

The understanding about the nature of actinic keratosis and the potential risk of this condition progressing to squamous cell carcinoma (SCC) is improving, among patients as well as healthcare providers. Especially among the elderly, actinic keratosis remains one of the most commonly diagnosed dermatological condition that creates a continued need for efficacious treatments.

To remain ahead of your competitors, request for a sample – https://www.futuremarketinsights.com/reports/sample/rep-gb-3233

Who Is Winning?

The actinic keratosis treatment market report tracks the key market players, which includes GlaxoSmithKline Plc. Nestle SA, Novartis AG, Sun Pharmaceutical Ltd., Leo Pharma Inc. etc. Leading manufacturers in the actinic keratosis treatment market are focusing on acquisitions to enhance their product portfolio. For instance, in November 2015, Leo Pharma A/S completed the acquisition of dermatology business of Astellas Pharma. With this acquisition, the company expanded its dermatology product portfolio segment. Companies are also focusing on segment leadership. In February 2016, Cipher Pharmaceuticals Inc. launched Actikerall for the topical treatment of slightly palpable and/or moderately thick hyperkeratotic actinic keratosis to mark their leadership in topical product segment.

Combination therapies such as topical fluorouracil cryotherapy, PDT and imiquimod therapy, chemical peels, and 5-FU are generally the most prescribed therapies for actinic keratosis. Convenient administration, lower potential for irritation, and systemic absorption continue to underpin their high adoption rate. Development of drugs with increased efficacy and decreased side effects that can be used as combination therapy for actinic keratosis treatment is currently the focal point of global market leaders. Biofrontera AG commercially launched its product Ameluz (2016), used in combination with PDT for actinic keratosis treatment.

Development of minimally invasive drug-device combination therapies and fast track regulatory approval for pipeline drugs will be offering a completely new set of treatment options for actinic keratosis in the near future.

Key Takeaways – Actinic Keratosis Treatment Market Study

  • Growing use of topical products as the first-line preference for actinic keratosis treatment is offering huge opportunities to market players to develop and launch new topical products for actinic keratosis treatment.
  • Increasing collaboration activities by key market players of the actinic keratosis treatment market with other companies to broaden their products portfolio is anticipated to propel the actinic keratosis treatment market growth.
    • For instance, in March 2017, Galderma SA (Nestle Skin Health Company) collaborated with Colorescience, to enhance its product portfolio for aesthetic treatment.
  • Increasing product approvals of actinic keratosis treatment by regulatory bodies is expected to fuel the actinic keratosis treatment market growth.
    • For instance, in March 2018, combination of Ameluz and daylight photodynamic therapy (PDT) by Biofrontera AG got approval from the European Union.
  • The U.S. and Australia marking rise in incidence and prevalence of actinic keratosis will remain highly prominent markets for actinic keratosis treatment providers.

Ask from Market Research Expert – https://www.futuremarketinsights.com/ask-question/rep-gb-3233

What Does the Report Cover?

Future Market Insights offers a unique perspective and actionable insights on actinic keratosis treatment market in its latest study, presenting historical demand assessment from 2014 – 2018 and projections from 2019 – 2029 on the basis of treatment category (topical treatment, procedural modality, photodynamic therapy and others), disease type (clinical AK and subclinical AK)and end-user (hospitals, laser therapy centers, private dermatology clinics, spas and rejuvenation centers, cancer treatment centers, homecare) in seven key regions.
Key Players :

  • Sun Pharmaceutical Industries Ltd.
  • Biofrontera
  • Nestle SA
  • Bausch Health Companies Inc.
  • Novartis AG
  • GlaxoSmithKline plc.
  • Almirall, LLC
  • LEO Pharma Inc.
  • Cipher Pharmaceuticals Inc.
  • Pierre Fabre Pharmaceuticals, Inc.

Request Discount @ https://www.futuremarketinsights.com/request-discount/rep-gb-3233

Actinic Keratosis Treatment Market By Category

By Treatment Type:

  • Topical Treatment
    • 5-fluorouracil Cream
    • Diclofenac Gel
    • Imiquimod Cream
    • Ingenol mebutate Gel
  • Procedural Modality
    • Chemical Peels
    • Cryotherapy
  • Photodynamic Therapy
  • Others

By Disease Type:

  • Clinical AK
  • Subclinical AK

By End User:

  • Hospitals
  • Private Dermatology Clinics
  • Laser Therapy Centers
  • Cancer Treatment Centers
  • Spas and Rejuvenation Centers
  • Homecare

More Trending Reports by Future Market Research :

Leukemia Therapeutics Treatment Market : During the forecast period, the leukemia therapeutics treatment market is expected to record a CAGR of 7.1 per cent to reach a valuation of US$ 17 Bn by 2024, from a valuation of US$ 13 Bn in 2020.

Non-invasive Surgical Wound Closure Market : The global non-invasive surgical wound closure market is estimated to be valued at US$ 2,192.3 billion in 2022. This market is expected to grow at a CAGR of 4.1% over the forecast period (2022-2032) to reach a market size of US$ 3,404.6 billion by 2032.

Mobile Cardiac Telemetry Systems Market : The global mobile cardiac telemetry systems market enjoys a valuation of US$ 825.3 Mn in 2021, and it is further projected to expand at a CAGR of 12.5% over the forecast years.

About FMI:

Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.

Contact Us:
Future Market Insights,
Unit No: 1602-006,
Jumeirah Bay 2,
Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers,
Dubai,
United Arab Emirates
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs

Brain Monitoring Systems Market is anticipated to progress at a CAGR of 5.9% to reach a valuation of US$ 6.56 Bn by the end of 2028

The brain monitoring systems market is projected to expand at a healthy pace with global sales exceeding US$ 3.5 Bn by end of 2019, as per the latest research study by FMI. A range of broad factors, including the government funding for development of advanced medical devices, and favorable healthcare reimbursements are key sales influencers of brain monitoring devices.

The FMI report finds that rising prevalence of brain aneurysm and chronic brain injuries have necessitated adoption of brain monitoring systems expediting early and effective treatment. According to the Brain Aneurysm Foundation, nearly 6 million individuals in the U.S. suffer from unruptured brain aneurysm. In the wake of such alarming statistics, the adoption of brain monitoring systems is surging at an impressive rate for revolutionizing patient care.

To remain ‘ahead’ of your competitors, request for a sample @ https://www.futuremarketinsights.com/reports/sample/rep-gb-1259

As per the study, demand for brain monitoring systems significantly took off in parallel with convergence of technology and healthcare, which translated into a massive influx of advanced medical devices with high functionality.

“Rising inclination toward non-invasive procedures is inducing a shift toward devices facilitating seamless observation and identification of neurons without involvement of invasive neurosurgery, such as brain monitoring systems,” says FMI report

The study opines EEG machines to gain significant momentum as widely-preferred brain monitoring systems, with revenues estimated to surpass US$ 1.5 Bn in 2019. Focus on delivering effective treatment via early detection of abnormalities have led the adoption of EEG machines, as these enable beneficial interventions with minimum chances of neurological complications. Simple platforms, effective report generator, and streamlined assessment tools are key attributes of EEGF machines that have driven their preference among patients and physicians alike.

Brain monitoring systems continue to witness significant demand from Hospitals (ICUS and adult care), with revenue expected to cross US$ 1 Bn in 2019. In response to high demand from hospitals, EEG machine manufacturers are implementing novel product development strategies, to realize enhanced profit margins.

Convergence of IOT with Brain Monitoring Space – A Key Trend Fostering Functionality with Better Connectivity

Penetration of IoT in the medical devices and systems landscape shows no signs of abating, evolving as a promising breakthrough that could result in connected ecosystems for brain monitoring devices with enhanced functionalities. IoT continues to play a major role in redefining interactions among various components of a brain monitoring system, thereby resulting in reduced costs, improved outcomes, and enhanced patient experiences. This trend is further complemented by on-going research efforts by prominent universities. For instance, a cohort of researchers at the Wits University of South Africa developed a way to connect human brains with internet on a real-time basis.

The transition toward miniaturized and portable models is gaining swift momentum in the brain monitoring systems landscape, as patients actively seek for advanced devices with new modalities, such as Functional Near-Infrared Spectroscopy (fNIRS), which enable real-time monitoring. The research study by FMI finds that future adoption of such upgraded versions will remain significant among physicians, as these facilitate seamless capture, storage, and processing of neurological information.

Get a Customized Scope to Match Your Need Ask an Expert- https://www.futuremarketinsights.com/ask-question/rep-gb-1259

Major players are making headway with strategic partnerships, acquisitions, and mergers to attain competitive advantages and access a wide-range range of resources and expertise. For instance, Philips acquired Electrical Geodesics, Inc. in 2017 with an objective to establish a new integrated neurological imaging, mapping and therapy guidance portfolio. Partnerships as such are foreseen to help in organic growth of the market players via collaborative innovations.

The FMI report covers assessment and forecast of the brain monitoring systems market for the period of 2018 to 2028. According to the report, the brain monitoring systems market is expected to grow at a CAGR of over 6% through 2028.

Competitive Landscape

This section of the report features profiles of key players operating in the brain monitoring systems market based on their market shares, differential strategies, brain monitoring systems product offerings, marketing approach and company dashboard.

Examples of some of the key players featured in this report include

Nihon Kohden Corporation., Electrical Geodesics, Inc. (Koninklijke Philips N.V.), Siemens Healthcare GmbH, Hitachi Ltd Natus Medical Incorporated, Medtronic plc. Compumedics Ltd, Neurosoft, EB Neuro S.p.A, and Ricoh Company Ltd among others.

The key manufacturers of brain monitoring systems are focusing on marketing strategies to increase both their product portfolio as well as geographical presence. The company’s manufacturing brain monitoring systems are focused on pricing strategies in order to lead in the market for brain monitoring systems.

Some other key market strategies followed by brain monitoring systems manufacturers include distribution & collaboration agreements to increase product reach, partnering with local as well as global retailers, and long-term partnerships with ambulatory surgical centers, clinics, hospitals and other distributor channels such as neonatal and pediatrics ICUs

Key Segment

Based on product type

fNIRS

EEG Systems

MEG Systems

MRI Systems

other brain monitoring systems

Based on modality

Portable/Handheld Systems

Standalone Systems

Based on end-users

hospitals

ambulatory surgical centers

clinics

pediatric & neonatal intensive care units

For critical insights, request for PDF Brochure: https://www.futuremarketinsights.com/reports/brochure/rep-gb-1259

Based on region

North America

Latin America

Western Europe

Eastern Europe

Asia Pacific Excluding Japan

China

Japan

MEA

About FMI:

Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 8-years.

Contact Us:
Future Market Insights,
Unit No: 1602-006,
Jumeirah Bay 2,
Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers,
Dubai,
United Arab Emirates
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs

3D Cell Culture Market stands at a net worth of US$ 1.15 Billion in 2022 | Get Insights FMI

The 3D cell culture market revenues surpassed US$ 778 million in 2018, as per a new FMI study. The market is estimated to grow at 7.8% y-o-y in 2019; key factors responsible for the projected market growth include,

  • A steady rise in global research and development expenditure
  • Efforts to leverage the potential of 3D cell culture to replace animal model testing
  • Increasing demand for biosimilar products
  • Extensive application of stem cell research and a growing emphasis on regenerative medicine

3D Cell Culture Market

Request Sample Copy of Report: https://www.futuremarketinsights.com/reports/sample/rep-gb-2843

The FMI study finds that scaffold-based 3D cell culture techniques are highly preferred over scaffold-free 3D cell culture. Owing to the significant adoption of scaffold-based 3D cell culture, the study finds that this technique garnered over 81% of the global market revenues.

Scaffold-based 3D cell culture techniques deliver researchers with additional functional operations in terms of material – natural or synthetic and different mechanical properties.

The technique uses either hydrogel-based support or polymeric hard material based support. Both types of supports find equivalent penetration in terms of application, however revenues garnered from polymeric hard material based support are higher.

According to the study, revenues of polymeric hard material based support held over half the scaffold-based 3D cell culture technique revenues in 2018 and the trend is expected to continue in the future.

“While 2D cell culture revolutionized the research efforts in stem cells, tissue engineering, and molecular biology, 3D cell culture has pushed the boundaries of traditional 2D cell culture technique with functional superiority. As the R&D efforts continue to rise in a bid to investigate the cause of different diseases and improve human health, 3D cell culture is set to remain a highly sought-after technique in the coming years,” says FMI.

Leading Manufacturers in the 3D Cell Culture Market:

  • Thermo Fisher Scientific Inc.,
  • Merck KGaA,
  • Becton,
  • Dickinson and Company, and Lonza,
  • Corning Incorporated,
  • Synthecon, Inc.

Competitive Landscape of the Global 3D Cell Culture Market

The competition section of the 3D cell culture market represents the profiles of the key players operating in the 3D cell culture market based on the products they offer and the total revenue of the companies. Some of the key players featured in this report include Thermo Fisher Scientific Inc., Merck KGaA, Becton, Dickinson and Company, Lonza, and Corning Incorporated.

The key manufacturers of 3D cell culture offer a wide range of products. Thermo Fisher Scientific, Inc. has developed a joint platform for advancing research in precision medicine.

Corning, one of the major leaders in 3D cell culture market, manufactures cell culture products, which include consumables (such as plastic vessels, specialty surfaces, cell culture media, and serum), as well as general labware and equipment, which are used for advanced cell culture research.

Download PDF Brochure @ https://www.futuremarketinsights.com/reports/brochure/rep-gb-2843

Application of 3D Cell Culture in Cancer Research Prominent

The FMI study estimates that 3D cell culture application in cancer research accounted for over 31% of the 3D cell culture market revenues in 2018. Cell culture is an integral part of cancer drug discovery practices. Greater strides are underway in the field to precisely characterize the diseases and develop advanced tumor cell lines using 3D cell culture techniques.

2D culture lines are considered as a standard for in vitro pre-clinical cancer treatment screening. However, more recently, the field is turning to 3D cell culture techniques to implement an ideal experimental model that mimics the human body environment to its best.

Stem cell technology is another lucrative field for 3D cell culture market. According to the FMI study, application in stem cell technology accounted for over one-fourth of the 3D cell culture market revenues in 2018. While 2D cell culture posed challenges of scalability in stem cell technology, apart from a few challenges, 3D cell culture has provided greater density and multi-fold expansion of the culture system in stem cell technology. Other fields that utilize 3D cell culture techniques are tissue regeneration, regenerative medicine, and drug discovery.

Revenues in North America Continue to Surge

North America continued to spearhead the revenues of 3D cell culture market during the historical period and the status-quo is likely to continue in the future. In 2018, North America accounted for over two-fifths of the global 3D cell culture market revenues. The study estimates that regional revenues are expected to grow at 8% in 2019 over 2018.

Funding in research and development, especially in cancer research remains higher in the United States as compared to other developed countries. Europe also presents significant funding in R&D activities. The FMI study finds that over one-fourth of the 3D cell culture market revenues were accounted for the Europe region in 2018, of which a bulk of revenues come from Western European countries such as Germany, the UK, France, Italy and Spain.

Key Segment Based on product type

  • scaffold-free 3D cell culture
  • scaffold-based 3D cell culture

Based on application

  • drug discovery
  • tissue regeneration & regenerative medicines
  • cancer research
  • stem cell technology
  • others

Based on end user

  • biotechnology and pharmaceuticals industries
  • hospital laboratories
  • academic research and institutes
  • contract research organizations

About FMI:

Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.

Contact Us:
Future Market Insights,
Unit No: 1602-006,
Jumeirah Bay 2,
Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers,
Dubai,
United Arab Emirates
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs

Loop-mediated Isothermal Amplification (LAMP) Market is projected to reach US$ 120.4 Million by 2028 | FMI

Global demand for loop-mediated isothermal amplification technology reached around US$ 85 million in 2018, as indicated by a new research study of Future Market Insights (FMI). Estimated to observe stable growth in revenue over the coming years, loop-mediated isothermal amplification market will witness dominance of DNA polymerase, among the various product types.

Dominance of DNA Polymerase Adoption to Prevail, LAMP Instruments to Emerge Lucrative

DNA polymerase will continue to find highest applicability in both research and diagnostics. According to FMI’s report, DNA polymerase will be the key revenue generating product in loop-mediated isothermal amplification market over the period of projection. However, the report also highlights that instruments such as turbidimeters and fluorescence measuring systems will prominent traction in loop-mediated isothermal amplification market through 2028.

Amongst various loop-mediated isothermal amplification technologies, micro-fluidic technology majorly, have been successfully used in the diagnosis of several diseases including malaria and tuberculosis. Loop-mediated isothermal amplification using DNA polymerase has seen a rapid rise in the past several years due to the high adoption of loop-mediated isothermal amplification in testing.

The application of these Loop-mediated isothermal amplification in assessing and directing diagnosis in certain types of disease, such as acute malaria, has provided a new dimension to the gradually growing field of minimal residual disease management.

To remain ‘ahead’ of your competitors, request for a sample – https://www.futuremarketinsights.com/reports/sample/rep-gb-5532

High Penetration of Cutting-edge Technology Molecular Diagnostics of Fatal Diseases to Push LAMP Market Growth

The simplicity sensibility and specificity of loop-mediated isothermal amplification puts it in a very good position for future development in life threatening disease diagnosis. It is anticipated that the loop-mediated isothermal amplification market will grow significantly during the forecast period, owing mainly due to demand for advanced molecular diagnostics to accurately diagnose life-threatening diseases.

In recent years, the detection and identification of nucleic acids using point-of-care total nucleic acid analysis systems and procedures are in rise including loop-mediated isothermal amplification in various clinical and industrial settings. Besides loop-mediated isothermal amplification has also challenged PCR based amplification as it could achieve enhanced nucleic acid amplification by increasing surface area to volume ratio with reduced testing cost.

Macroeconomic indicators such as government funding for advancement and increased research on disease epigenetics; establishment of network of distribution and marketing agreements to ensure availability of products to different loop-mediated isothermal amplification end users globally; liberalization of import and export trade on point of care diagnostic devices and chemical reagents are also anticipated to propel the growth of the loop-mediated isothermal amplification market.

Key Challenges Facing Development of Loop-mediated Isothermal Amplification Market

On the grey side, loop-mediated isothermal amplification has several intrinsic disadvantages such as its amplification method is devoid of an internal PCR inhibition control (IC). It is essential to perform all the reactions in duplicate, one being or the target and the other one for the IC in loop-mediated isothermal amplification assay.

Moreover, most standard DNA polymerases are unable to exhibit activity in samples derived from crude lysate due to the presence of polymerase inhibitors. This adds complexity to the loop-mediated isothermal amplification processing due to additional steps involved in purifying DNA to be used for amplification, which could also result in loss of starting material.

Get a Customized Scope to Match Your Need Ask an Expert- https://www.futuremarketinsights.com/ask-question/rep-gb-5532

Loop-Mediated Isothermal Amplification Market: Additional Questions Answered

  • What is the revenue potential of the Loop-Mediated Isothermal Amplification Markets across North America and Europe?
  • Who are the key competitors and what are their portfolios in the Loop-Mediated Isothermal Amplification Market?
  • What are the major challenges influencing the growth of the Loop-Mediated Isothermal Amplification Market?
  • How is intervention from regulatory authorities shaping the growth of the Loop-Mediated Isothermal Amplification Market?

Regions with High Disease Prevalence to Reflect High Growth Potential for LAMP Market

Due to increase in prevalence of malaria and other pandemic diseases, regions such as East and South Asia are anticipated to be the fastest growing regional loop-mediated isothermal amplification markets and are poised to offer tremendous opportunities to key players. The increase in disease prevalence will increase the demand for the use of loop-mediated isothermal amplification for point-of-care diagnosis. Besides, distribution & collaboration agreements by leading players of loop-mediated isothermal amplification products with the established local distributors in the regions will fuel the market growth of both the regions.

The loop-mediated isothermal amplification market report tracks some of the key companies operating in the global loop-mediated isothermal amplification market such as :

  • Eiken Chemcial Co.Ltd
  • New England Biolabs
  • Jena Bioscience GmbH
  • NIPPON GENE CO.
  • LTD
  • HUMAN
  • Optigene
  • HiberGene Diagnostics
  • Meridian Bioscience Inc.
  •  Mast Group Ltd.

Key Segment

Based on product type

  • instruments
    • incubation systemsTurbidimeters
    • Agarose gel electrophoresis
    • fluorescence measuring systems
  • kits & reagents
    • DNA polymerase
    • Primer Mix
    • DNA Polymerase &Primer mix
    • dyes
    • other reagents

Based on Technology

  • microfluidic technology
  • advanced infrared optical technology
  • modern microsystem technology

Based on Application

  • diagnostic
  • research purpose

For critical insights, request for PDF Brochure: https://www.futuremarketinsights.com/reports/brochure/rep-gb-5532

Based on End User

  • hospital & laboratories
  • research & academic institutes
  • others

About FMI:

Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 9-years.

Contact Us:
Future Market Insights,
Unit No: 1602-006,
Jumeirah Bay 2,
Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers,
Dubai,
United Arab Emirates
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs

Hematology Diagnostics Market Is estimated To Reach US$ 1.2 Billion by the End of 2031 | FMI

Standing at a valuation of US$ 725 Mn in 2022, the global hematology diagnostics market is projected to reach US$ 1.2 Bn by the end of 2031. Demand for hematology diagnostics is anticipated to increase at a CAGR of 5.8% from 2022 to 2031.

The Hematology Diagnostics Market has witnessed the advent of a wide range of hematology testing solutions that combine the attributes of strainer, slider maker, and cell counter. Integrated solutions have been gaining ground in the hematology diagnostics market, as growing work load has prompted pathologists to adopt methods with precision and accuracy for improved results.

Request a report sample to gain comprehensive insights at https://www.futuremarketinsights.com/reports/sample/rep-gb-9046

According to a recent study of Future Market Insights (FMI), the hematology diagnostics market recorded a valuation of approximately US$ 3,500 Mn in 2017. Growing popularity of modern day analyzers that offer five to seven parts white cell differential analysis, along with additional information on cell population data (CPD), large unstained cell population, and granularity index, will continue to drive growth of the hematology diagnostics market.

The study opines that the hematology diagnostics market will continue to remain a consolidated landscape, with few established players collectively accounting for a larger share of the market. Robust portfolio, and stronger distribution footprint of these leading players, including F. Hoffmann-La Roche Ltd., Beckman Coulter, Inc., Abbott Laboratories, and Sysmex Corporation, will continue to uphold their lead in the hematology diagnostics market in the upcoming years.

Key players in the hematology diagnostics market are focusing on strategic partnerships with vendors having innovative technologies, to gain a greater share with more diverse portfolios. Other leading players profiled in the report on the hematology diagnostics market include HORIBA, Ltd., HemoCue AB, Mindray Medical International Limited, Danaher (Beckman Coulter, Inc.), Bio-Rad Laboratories, Inc., and Siemens Healthineers.

For any Queries Related with the Report, Ask an Analyst @ https://www.futuremarketinsights.com/ask-question/rep-gb-9046

Emphasis on Effective Hematology Diagnostics to Surge in Line with Prevalence of Blood Cancer

There has been a marked rise in the prevalence of blood disorders, and the pervasiveness of these ailments will continue to surge in the foreseeable future, according to the report. This has further driven the essentiality of hematology diagnostics with greater efficacy, thereby complementing new product developments and technological advancements in the hematology diagnostics market worldwide.

Recent studies from associated regulatory authorities estimated that, in the US alone, number of individuals affected with blood-related disorders reached nearly 173,000 in 2017. This has further led the healthcare institutes and governments to take up initiatives for increasing awareness of these disorders and the availability of related management & treatment procedures, which in turn has led the demand and adoption of hematology diagnostics in the recent past.

Point-of-care testing has also witnessed a notable rise in demand, with technological advancements leading to results with higher accuracy and convenience. Easy availability of myriad test methods for hematology diagnostics has also been a key factor driving growth of the market. The study estimates that the hematology diagnostics market

We Offer tailor-made Solutions to fit Your Requirements, Request Customization @ https://www.futuremarketinsights.com/customization-available/rep-gb-9046

Gains from Hematology Diagnostics Market in Developed Markets to Remain Higher

The study anticipated Europe and North America to remain the most lucrative markets for the hematology diagnostics market. Relatively greater prevalence of blood-related disorders, higher awareness about the existing screening techniques for blood disorders, and rising expenditure on health & wellness by consumers, allude greater gains from the hematology diagnostics market in Europe and North America.

Sensing varied requirements of the healthcare settings and the distinctions in the blood ailments, key players in the hematology diagnostics market have introduced a wide range of hematology instruments, According to the study, hematology analyzers currently accounts for the largest share in the hematology diagnostics market.

About FMI:

Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.

Contact Us:
Future Market Insights,
Unit No: 1602-006,
Jumeirah Bay 2,
Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers,
Dubai,
United Arab Emirates
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs

Benign Prostatic Hyperplasia (BPH) Prostate Treatment Market is projected to attain a valuation of US$ 39.5 Billion by 2028

The approximately US$ 25 Bn market for benign prostatic hyperplasia prostate treatment is likely to expand at 4.6% CAGR during 2018-2028, according to a recent research report of Future Market Insights (FMI). The report has envisaged steady growth prospects for the revenue of global benign prostatic hyperplasia prostate treatment market through 2028.

The World Population Prospects’ data (2017) projected that the number of individuals aged 60 years and above will double by 2050, and triple by 2100. With such a high pace estimated for the growth of population aged 60 years and above, it is more likely that the prevalence of aging related health conditions will also increase at a considerable pace in the years to come. A high prevalence rate of benign prostatic hyperplasia (BPH) in men, the demand for improved and more effective treatment options continues to increase at a high rate.

Request Sample Copy of Report: https://www.futuremarketinsights.com/reports/sample/rep-gb-16464

Alpha-blockers & Drugs for Lower UTIs Remain Pivotal in Benign Prostatic Hyperplasia Prostate Treatment

The drug treatment has been vital in treating benign prostatic hyperplasia conditions and lower UTIs, which has been attributed to widespread availability of drug-based benign prostatic hyperplasia prostate treatment. This factor, in particular, will play an instrumental role in driving the growth of the benign prostatic hyperplasia prostate treatment market during the forecast period. Drugs will remain the first choice of treatment for benign prostatic hyperplasia.

Benign prostatic hyperplasia increases the risk of other disorders as well. The most common disorder caused due to benign prostatic hyperplasia is lower UTI (urinary tract infection) for which, Alpha-blockers constitute the first line of treatment. However, other drugs are also available in the market, which offer relief from the benign prostatic hyperplasia symptoms. Other drugs include alpha reductase inhibitors, phosphodiesterase-5 (PDE-5) inhibitors, muscarinic receptor antagonists, and combination drugs.

Key Players:

  • Pfizer, Inc.,
  • Valeant Pharmaceuticals Inc.,
  • Novartis AG,
  • Bayer AG,
  • Sanofi S.A.,
  • GlaxoSmithKline plc.,
  • Bristol-Myers Squibb and Company,
  • Teva Pharmaceutical Industries Ltd,
  • Mylan N.V.,
  • Merck & Co.,
  • Cardinal Health Inc., and
  • Eli Lilly and Company among others.

Additional Questions Answered

Additional questions addressed in this benign prostatic hyperplasia prostate treatment market report are:

  • What is the revenue potential of the benign prostatic hyperplasia prostate treatment market across North America and Europe?
  • Who are the key players and what are their product portfolios in the benign prostatic hyperplasia prostate treatment market?
  • What are the major challenges impacting the growth of the benign prostatic hyperplasia prostate treatment market?
  • How is the involvement from key regulatory bodies shaping the growth of the benign prostatic hyperplasia prostate treatment market?

Ask from the Market Research Expert @ https://www.futuremarketinsights.com/ask-question/rep-gb-1664

Demand for Benign Prostatic Hyperplasia Prostate Treatment Higher in Developed Regions, Patient Pool Expanding Steadily in Developing Markets

Owing to significantly growing prevalence of benign prostatic hyperplasia in North American men, benign prostatic hyperplasia prostate treatment market is expected to witness strong growth within the region, followed by Europe.

Extensive availability of benign prostatic hyperplasia prostate treatments, increasing clinical trials, improving R&D scenario, higher healthcare spending, and favorable government initiatives will continue to assist the growth of the benign prostatic hyperplasia prostate treatment market in developed regions.

On the other side, Asia Pacific’s benign prostatic hyperplasia prostate treatment market is foreseen to witness significant growth, owing to steadily expanding patient pool due in the region.

UroLift System to Revolutionize the Competitive Landscape of Benign Prostatic Hyperplasia Prostate Treatment Market

Teleflex Incorporated’s NeoTract recently launched UroLift® System as a highly effective, least invasive option for benign prostatic hyperplasia prostate treatment. The UroLift® System is permanently implanted via a transurethral outpatient procedure and predominantly relieves prostate obstruction, which is one of the primary symptoms of benign prostatic hyperplasia. The company has also declared insurance coverage for UroLift® System. While the coverage is being provided by Humana, it is most likely to improve awareness about increasing availability and broadening access of minimally invasive treatment methods in urological conditions such as benign prostatic hyperplasia. This in turn will encourage adoption of UroLift® System among patients seeking effective benign prostatic hyperplasia prostate treatment.

A majority of patients with enlarged prostate continue to perceive medication and surgery as the only available treatment alternatives. However, an increasing number of physician recommendations is advocating the use of The UroLift® System as it eliminates side effects associated with other conventional options of benign prostatic hyperplasia prostate treatment.

For more insights on the overall performance of global benign prostatic hyperplasia prostate treatment market through 2028, write to press@futuremarketinsights.com

Key Segment

Based on treatment type

  • alpha-blockers
  • alpha reductase inhibitors
  • phosphodiesterase-5 (PDE-5) Inhibitors
  • muscarinic receptor antagonist
  • combination drugs

Based on distribution channel

  • institutional sales
  • retail sales
  • online pharmacies

About FMI:

Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.

Contact Us:
Future Market Insights,
Unit No: 1602-006,
Jumeirah Bay 2,
Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers,
Dubai,
United Arab Emirates
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs